SEPN - NASDAQ

Septerna, Inc.

SEPN·NASDAQ

$31.38

+4.8%

HealthcareBiotechnology

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products candidates for the treatment of endocrinology, immunology and inflammation, and metabolic diseases. The company develops SEP-786, an oral small molecule PTH1R agonist for hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 NAM for chronic spontaneous urticaria and other mast cell diseases; TSHR Program, an oral small molecule TSHR NAM for Graves' disease and thyroid eye disease. It also develops oral small molecule single- and multi-incretin receptor agonists for metabolic disorders including obesity and type 2 diabetes. Septerna, Inc. was formerly known as GPCR NewCo, Inc. and changed its name to Septerna Inc. in June 2021. The company was incorporated in 2019 and is headquartered in South San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$1.41B

EPS-1.1000

P/E Ratio-28.52

Earnings Date08/10/2026

sepn

Cash at Beginning of Period

Last Annual Value

239.10M

3-Year CAGR

109%

5-Year CAGR

56%

10-Year CAGR

25%

Adjust for Inflation

Septerna, Inc. Competitors Analysis of Cash at Beginning of Period

SEPN · NASDAQ

Company	Cash at Beginning of Period	CAGR 3Y	CAGR 5Y	CAGR 10Y
Septerna, Inc. NASDAQ:SEPN	239.10M	96.6%	N/A	N/A
ProKidney Corp. NASDAQ:PROK	99.12M	-41.3%	85.0%	N/A
Prime Medicine, Inc. NASDAQ:PRME	196.54M	-0.8%	39.7%	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	99.85M	1.5%	17.3%	18.0%
Bicara Therapeutics Inc. Common Stock NASDAQ:BCAX	489.71M	390.2%	N/A	N/A
Tango Therapeutics, Inc. NASDAQ:TNGX	72.10M	4.1%	18.7%	N/A
Fortrea Holdings Inc. NASDAQ:FTRE	118.50M	2.4%	8.1%	N/A
Arbutus Biopharma Corporation NASDAQ:ABUS	36.33M	5.7%	-7.0%	-14.1%
Nurix Therapeutics, Inc. NASDAQ:NRIX	110.00M	18.9%	-1.6%	N/A
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	322.40M	-20.1%	6.4%	N/A
Kura Oncology, Inc. NASDAQ:KURA	224.46M	63.0%	-7.2%	30.7%

Septerna, Inc. Fair Value Envelope

SEPN · NASDAQ

Our analysis suggests that SEPN has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $31.375, this represents a potential HIDDEN relative to our calculated worth for Septerna, Inc..

HIDDEN

Intrinsic Value

Current Price: $31.375

Related Guides

Blog Categories

Continue your SEPN research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.